-
Company Insights
Innovation and Patenting activity of ISU Chemical Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ISU Chemical Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
Hemolytic Uremic Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemolytic Uremic Syndrome - Drugs In Development, 2023’, provides an overview of the Hemolytic Uremic Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemolytic Uremic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hemoglobinuria – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemoglobinuria - Drugs In Development, 2023’, provides an overview of the Hemoglobinuria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Paroxysmal Nocturnal Hemoglobinuria – Drugs In Development, 2023
Global Markets Direct’s, ‘Paroxysmal Nocturnal Hemoglobinuria - Drugs In Development, 2023’, provides an overview of the Paroxysmal Nocturnal Hemoglobinuria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Drugs In Development, 2023’, provides an overview of the Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers...
-
Product Insights
Hemophilia B (Factor IX Deficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemophilia B (Factor IX Deficiency) - Drugs In Development, 2023’, provides an overview of the Hemophilia B (Factor IX Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemophilia B (Factor IX Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...